SKB264

Sacituzumab tirumotecan (SKB264, MK-2870) is a TROP2-directed antibody-drug conjugate developed by Sichuan Kelun-Biotech and licensed to Merck for territories outside greater China. Under the May 2022 option exercise, Merck paid $35M upfront and Kelun is eligible for up to ~$901M in downstream milestones ($82M development, $334M regulatory, $485M sales-based) plus tiered mid-single to low-double-digit royalties [1]. The antibody binds TROP2, a surface protein present on most solid tumor cells, and delivers a topoisomerase I inhibitor payload (KL610023, a belotecan derivative) inside those cells to break their DNA and kill them. Merck is running at least six Phase 3 trials across previously treated non-small cell lung cancer with actionable driver mutations, ovarian, cervical, urothelial, and breast cancers, while Kelun already secured China NMPA approval in third-line triple-negative breast cancer in May 2024 [2]. This is one of Merck's most important post-Keytruda oncology hedges and it goes head-to-head with AstraZeneca/Daiichi Sankyo's datopotamab deruxtecan (Datroway) and Gilead's sacituzumab govitecan (Trodelvy) in the same target space.

Sacituzumab tirumotecan is a novel biologic that first won regulatory clearance in China (NMPA) in May 2024 for triple-negative breast cancer after two or more prior therapies, based on the OptiTROP-Breast01 Phase 3 study [2]. Whether the OptiTROP-Breast01 dataset alone can support a US filing is uncertain. Chinese-only Phase 3 data can be supplemented for FDA submissions when bridging studies are provided, but Merck's public communications suggest the ex-China regulatory strategy will lean on the TroFuse global program rather than on the Kelun NMPA package. There are no US or EU approvals yet. The global program is now anchored by Merck under the TroFuse trial naming scheme. The nearest readout is MK-2870-004, in previously treated advanced non-squamous NSCLC with EGFR mutations or with other actionable driver alterations (ALK, ROS1, BRAF V600E, NTRK, MET exon 14 skipping, RET), after progression on 1-2 prior tyrosine kinase inhibitors (TKIs, small-molecule drugs that block driver-mutant kinase signaling) plus a platinum-based therapy [3, 8]. The trial has completed enrollment (n=556, ACTIVE_NOT_RECRUITING) with overall survival as the primary endpoint. Additional Phase 3 studies are actively recruiting in first-line cervical cancer maintenance with pembrolizumab (MK-2870-036, n=1023) [4], platinum-sensitive recurrent ovarian cancer maintenance (MK-2870-022, n=770) [5], and urothelial cancer (MK-2870-031, n=590) [6]. Merck has not publicly disclosed FDA breakthrough or fast-track designations for the asset in any indication as of mid-2026, though the company has flagged sacituzumab tirumotecan as a top-tier pipeline priority on multiple earnings calls [7]. First BLA filing timing has not been formally guided; Merck has not committed to a specific quarter for MK-2870-004 topline data.

TROP2 (encoded by TACSTD2) is a cell-surface protein that sits on the outer membrane of most epithelial tumor cells and is only weakly expressed on normal tissues. It behaves loosely like a growth-signal amplifier, and its high expression correlates with worse outcomes in breast, lung, and gastric cancers. That expression pattern makes it an attractive delivery address for a targeted payload rather than a signaling target you have to shut off. Sacituzumab tirumotecan is a humanized IgG1 antibody conjugated via a proprietary 2-methylsulfonyl-pyrimidine (Kthiol) bifunctional linker to KL610023, a proprietary belotecan derivative that inhibits topoisomerase I and breaks tumor DNA during replication. The average drug-to-antibody ratio is 7.4 [11]. The linker is designed to be stable in circulation and to release the payload preferentially in the acidic tumor lysosome. The mechanism is validated at the target level: sacituzumab govitecan (Trodelvy) is approved and generated roughly $1.3B in worldwide sales for Gilead in 2024 [12], and datopotamab deruxtecan won FDA approval in January 2025 for hormone-receptor-positive, HER2-negative metastatic breast cancer covering IHC 0, IHC 1+, and IHC 2+/ISH- tumors (essentially the full HER2-negative population), and again in June 2025 for first-line immunotherapy-ineligible triple-negative breast cancer [13]. The open scientific question is not whether TROP2 ADCs work; it is whether SKB264's specific linker chemistry and higher DAR translate into a better therapeutic index than the competition, especially on interstitial lung disease and stomatitis.

The lead late-stage study is MK-2870-004 (NCT06074588), a Phase 3 open-label randomized trial in previously treated non-squamous NSCLC with EGFR exon 19del or L858R mutations, less common EGFR mutations (exon 20 S768I, exon 21 L861Q, exon 18 G719X), or other actionable driver alterations in ALK, ROS1, BRAF V600E, NTRK, MET exon 14 skipping, or RET [3, 8]. Patients must have progressed on 1-2 prior TKIs plus a platinum-based regimen. Patients get sacituzumab tirumotecan versus investigator-choice chemotherapy (docetaxel or pemetrexed), with overall survival as the primary endpoint and n=556 enrolled. EGFR-mutant patients are the largest sub-population by enrollment, but the inclusion of other driver alterations broadens the potential label and makes the eventual commercial opportunity larger than a pure EGFR-mutant NSCLC framing suggests. The design draws heavily on the positive Phase 2 signal from Zhao et al. published in Nature Medicine 2025, which reported an objective response rate of 43.6% and median progression-free survival of 11.1 months in EGFR-mutated NSCLC after TKI failure, without ICI combination [9]. The Phase 2 dataset is largely confined to EGFR-mutant patients, so the extrapolation of that ORR to the broader Phase 3 population is an assumption rather than a demonstrated result. MK-2870-036 in first-line cervical cancer maintenance (n=1023, with pembrolizumab) is a much bigger bet and pairs sacituzumab tirumotecan with Merck's biggest asset [4]. MK-2870-022 in ovarian maintenance (n=770) uses standard-of-care comparator and includes a safety run-in [5]. Enrollment is also underway in a smaller investigator-initiated Chinese Phase 2 combining SKB264 with inetetamab in HER2-positive breast cancer after T-DXd failure (NCT07182721) [10], which is a niche but interesting signal-finding effort. Notably, there is no publicly disclosed head-to-head Phase 3 comparison of SKB264 vs. Trodelvy or SKB264 vs. Datroway; differentiation will have to be inferred from cross-trial comparisons in overlapping populations rather than proven directly.

Our model estimates a 22% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

The dominant safety risk is on-target ADC toxicity from the topoisomerase I payload class: stomatitis, neutropenia, and interstitial lung disease (ILD). Both Trodelvy and Enhertu carry black-box warnings for related toxicities, and any ILD signal in the Merck Phase 3s could gate the label or force a dose reduction that erodes efficacy. In the published Nature Medicine Phase 2 in EGFR NSCLC, the most common Grade 3+ adverse events were neutropenia, anemia, and stomatitis, with a manageable but non-trivial rate of pneumonitis [9]. Competitive risk is the second-biggest concern. Datroway (datopotamab deruxtecan) was approved by FDA in January 2025 for HR+/HER2-negative (IHC 0, 1+, 2+/ISH-) metastatic breast cancer [13], covering essentially the full HER2-negative slice of HR+ disease, ahead of any Merck breast filing for SKB264. Datroway also received first-line approval in immunotherapy-ineligible metastatic TNBC in June 2025, directly encroaching on the Trodelvy TNBC franchise that SKB264 also targets. That means the U.S. TROP2 ADC market in HR+/HER2- and in 1L TNBC will already have an entrenched Daiichi/AZ franchise by the time Merck files. In 2L+ TNBC, Trodelvy holds the established position. Merck's differentiation pitch has to lean on cross-indication breadth (cervical, ovarian, urothelial), where Datroway is less advanced, or on cross-trial efficacy and safety comparisons in overlap indications, since no head-to-head Phase 3 vs. Trodelvy is currently disclosed. Execution risk is moderate: MK-2870-036 in first-line cervical maintenance is n=1023, which is a large and slow-recruiting design. Commercial risk if approved is real: ADC pricing typically runs $150K-$200K per patient-year and payer scrutiny on incremental benefit versus Datroway and Trodelvy will be sharp. Composition-of-matter patent and regulatory exclusivity timelines for SKB264 have not been publicly detailed by Kelun or Merck in a way that permits a confident peak-sales window; the primary Kelun composition patents were filed in the late 2010s, suggesting a nominal patent life into the mid-to-late 2030s, but this should be verified against the specific patent family and jurisdictions before it is used for valuation.

Worth watching, and not just noise. This is one of Merck's largest oncology ADC bets and one of the most consequential pipeline assets in solid-tumor oncology for the 2026-2028 window. The single highest-value catalyst is the MK-2870-004 readout in previously treated driver-mutant NSCLC, which is the nearest to reporting given active-not-recruiting status; Merck has not publicly committed to a specific quarter, so any dated timing estimate should be treated as conjecture until an earnings call guides it. A positive OS hit in that trial with a clean ILD profile would open an accelerated-approval path in the U.S. and validate the payload chemistry against the Datroway comparison. A miss, especially on ILD, would materially damage the entire cross-indication franchise. The cervical and ovarian maintenance readouts (MK-2870-036 and MK-2870-022) are 2027-2028 events and matter more for peak revenue than for near-term stock movement. Track Merck's quarterly R&D commentary for guidance on filing timing, and watch for any AstraZeneca/Daiichi Sankyo Datroway label expansions in the interim: each Datroway approval narrows the greenfield Merck can capture. Check back after MK-2870-004 topline. For portfolio-tracking purposes, Kelun-Biotech (HKG:6990) captures upside via China royalties and milestone payments, but the value driver here is Merck's global execution.